Ciara Kelly, MBBCh, BAO

home / authors / ciara-kelly-mbbch-bao

Articles

Ciara Kelly, MBBCh, BAO

Dr Kelly on Ongoing Trials in Patients With GIST

Ciara Kelly, MBBCh, BAO
August 26th 2024

Ciara Kelly, MBBCh, BAO, discusses ongoing trials to further enhance the treatment of patients with gastrointestinal stromal tumor.

Read More

Ciara Kelly, MBBCh, BAO

Dr Kelly on the Evaluation of the Combination of Ripretinib and DCC-3116 in GIST

Ciara Kelly, MBBCh, BAO
August 23rd 2024

Ciara Kelly, MBBCh, BAO, discusses the evaluation of DCC-3116 in combination with ripretinib in advanced gastrointestinal stromal tumor.

Read More

Ciara Kelly, MBBCh, BAO

Dr Kelly on the Importance of Testing For Genetic Abnormalities in GIST

Ciara Kelly, MBBCh, BAO
August 21st 2024

Ciara Kelly, MBBCh, BAO, discusses the importance of genetic abnormality testing for patients with gastrointestinal stromal tumors.

Read More

Ciara Kelly, MBBCh, BAO

Dr Kelly on the Treatment and Heterogeneity of GIST

Ciara Kelly, MBBCh, BAO
August 7th 2024

Ciara Kelly, MBBCh, BAO, discusses how the heterogeneity of GIST affects treatment decisions and the importance of testing for genetic abnormalities.

Read More

Nam Bui, MD, sarcoma specialist, clinical assistant professor, medicine, Stanford Cancer Institute; Ciara Kelly, MBBCh, BAO, interim clinical director, Sarcoma Oncology Service, Memorial Sloan Kettering Cancer Center

Bui and Kelly Discuss the Utility of Nab-Sirolimus in Advanced Malignant PEComa

Nam Bui, MD;Ciara Kelly, MBBCh, BAO
July 18th 2024

Drs Bui and Kelly discuss key long-term findings from the AMPECT trial investigating nab-sirolimus in patients with advanced malignant PEComa.

Read More

Ciara Kelly, MBBCh, BAO

Dr Kelly on the Role of Ripretinib in the GIST Treatment Paradigm

Ciara Kelly, MBBCh, BAO
July 16th 2024

Ciara Kelly, MBBCh, BAO, discusses the current and potential roles for ripretinib in the gastrointestinal stromal tumor treatment paradigm.

Read More

Latest Updated Articles

Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors
Published: August 22nd 2024 | Updated: August 29th 2024
Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors
Long-term Follow-up of Selinexor Maintenance for Patients With TP53wt Advanced or Recurrent Endometrial Cancer: A Prespecified Subgroup Analysis From the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study
Published: August 6th 2024 | Updated: August 19th 2024
Long-term Follow-up of Selinexor Maintenance for Patients With TP53wt Advanced or Recurrent Endometrial Cancer: A Prespecified Subgroup Analysis From the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study
Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
OncLive’s August Roundup of Key FDA Approvals in Oncology
Published: September 4th 2024 | Updated: September 8th 2024
OncLive’s August Roundup of Key FDA Approvals in Oncology
Paula Rodriguez-Otero, MD, PhD
Published: June 4th 2024 | Updated: September 8th 2024
D-VRd Boosts MRD-Negativity Rates in Newly Diagnosed, Transplant-Eligible Multiple Myeloma